时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
研究问题
Aim The aim of this narrative review is to explore and synthesize current knowledge on the adaptive responses of breast cancer cells to oxygen stress, with a particular focus on the mechanisms by which these cells survive and proliferate in hypoxic tumor microenvironments.；These new blood vessels aim to re-establish oxygen and nutrient delivery to the hypoxic tumor zones.；The balance between adaptive and terminal UPR signaling is therefore a critical determinant of whether oxygen-stressed breast cancer cells survive.
方法
Literature search strategy A comprehensive literature search was conducted across major biomedical databases, including PubMed, Scopus, Web of Science, and Google Scholar.；Methodological considerations No quantitative meta-analysis was performed due to variability in experimental models, endpoints, and clinical contexts.
核心结论
Through coordinated activation of hypoxia-inducible signaling pathways, breast cancer cells enhance angiogenesis, rewire metabolism toward glycolysis, suppress immune surveillance, and acquire invasive and stem-like phenotypes that collectively promote tumor progression and metastasis.
局限
However, under hypoxia, cancer cells shift toward glycolysis, a less efficient but oxygen-independent pathway, to sustain their energy needs.；However, the resulting vasculature is often structurally and functionally abnormal, leading to inefficient perfusion and fluctuating oxygen levels, thereby perpetuating a cycle of hypoxia and further tumor adaptation ( 11 , 12 ).
对本项目的价值
中等价值：属「营养感知—自噬—蛋白稳态轴」方向；肿瘤相关衰老机制（交叉参考）栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.9/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 59,758 字符，题名指纹 1.00，已过 DOI 逐字 + 题名指纹 + 正文长度三重归属校验）
原文题录
- 中文题名：乳腺癌对氧应激的适应：肿瘤存活、进展与治疗抵抗机制
- 英文标题：Breast cancer adaptation to oxygen stress: mechanisms of tumor survival, progression, and therapeutic resistance.
- 期刊与标识：Oncol Rev · PMID 42964571 · DOI 10.3389/or.2026.1959034 · PMC PMC13720365 · EDAT 2026-10-31